Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
Summary
The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity than MRI alone for identifying recurrence or failure in patients undergoing focal therapy.
Arms & interventions
Outcome measures
Primary
Sensitivity of PSMA PET/MRI
Sensitivity of PSMA PET/MRI for detecting clinically significant prostate cancer at 12 months post HIFU, defined as the portion of patients with clinically significant cancer on the 12-month biopsy (reference standard) who had a positive PSMA PET/MRI.
Time frame: Month 12
Oncologic Control
Oncologic control at 12 months, defined as the absence of cancer, determined by the scheduled biopsy at 12 months.
Time frame: Month 12
Secondary
Portion of patients achieving a PSA reduction greater than 50%
Time frame: Month 3, Month 6, Month 12
Change in IPSS (International Prostate Symptom Score)
Time frame: Baseline, Month 12
Change in SHIM (Sexual Health Inventory for Men) Score
Time frame: Baseline, Month 12
Eligibility criteria
Study locations (1)
NYU Langone Health
New York, New York, 10016